Table 2.
Multiple linear regression models for aciclovir and CMMG CSF concentrations in 21 patients treated with aciclovir for CNS infection (34 samples)
| Independent variable | Comparison | Aciclovir CSF concentration |
CMMG CSF concentration |
||
|---|---|---|---|---|---|
| β (95% CI) | P value | β (95% CI) | P value | ||
| Albumin ratio (×10−3) | per 10 unit increase | 1.499 (1.290–1.709) | <0.0001 | 0.388 (0.356–0.421) | <0.0001 |
| Lag time dose to sampling (h) | per 1 unit increase | −0.779 (−1.350 to −0.208) | 0.015 | −0.046 (−0.072 to −0.020) | 0.0038 |
| Creatinine clearance (mL/min) | per 10 unit increase | −1.428 (−2.099 to −0.756) | 0.0015 | −0.161 (−0.245 to −0.077) | 0.0027 |
| Dose (mg/kg) | per 1 unit increase | 1.703 (1.215–2.190) | <0.0001 | 0.093 (0.022–0.163) | 0.017 |
| Weight (kg) | per 10 unit increase | 1.996 (1.000–2.991) | 0.0005 | 0.223 (0.052–0.394) | 0.013 |
| Age (years) | per 10 unit increase | 0.042 (−1.402 to 1.487) | 0.95 | −0.026 (−0.198 to 0.147) | 0.74 |
| Gender | women versus men | 0.774 (−2.276 to 3.824) | 0.60 | 0.292 (−0.179 to 0.762) | 0.21 |